NCT02637973View on ClinicalTrials.gov

Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

August 31, 2018

Study Completion Date

August 31, 2018

Conditions
Type 2 DiabetesNon-alcoholic Fatty Liver Disease
Interventions
DRUG

Empagliflozin

25 mg once daily

DRUG

Placebo

once daily

Trial Locations (5)

Unknown

Charite Universitaetsmedizin Berlin, Berlin

German Diabetes Center, Düsseldorf

University Clinic Heidelberg, Heidelberg

University Clinic Tübingen, Tübingen

01307

Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden

Sponsors

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

lead

The Deutsche Diabetes Forschungsgesellschaft e.V.

OTHER

NCT02637973 - Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes | Biotech Hunter | Biotech Hunter